Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 573-576, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-862880
ABSTRACT
At present, there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma (NHL). Histone deacetylase inhibitors (HDACi) exert anti-tumor effects by inhibiting the activation of histone deacetylase (HDAC) and regulating gene expression. HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL. This article reviews the progress of HDACi in the treatment of NHL.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS